Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

February 9, 2018: By Jon Swedien

Two Pennsylvania investment groups announced Feb. 5 that they have made a $500 thousand joint investment in Ocunova Inc., a spinout from the Penn State University College of Medicine.

Ocunova’s drug candidate, OCU-001, is designed to affect the underlying cause of dry eye disease in diabetes patients, Ocunova CEO Michael Shine said.

A study published in 2014 in the American Diabetes Association’s journal, Diabetes Care, indicated that half of all diabetes patients suffer from dry eye. Study authors noted that nerve disease is a common complication of diabetes, and the most common form, polyneuropathy, can damage corneal nerves, hindering a person’s ability to make tears and slowing the blink rate, causing tears to evaporate.

Ocunova will use the funding to develop OCU-001, the organizations said.

The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) and Ben Franklin Technology Partners/CNP made the joint investment.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility